ASCO50周年肠道肿瘤治疗进展(2014-10-9)题材.ppt

Median PFS was also substantially increased, from 6.2 months with IFL + placebo to 10.6 months with IFL + bevacizumab. These data are highly statistically significant (P0.001). The median survival of patients in this trial was 15.6 months for patients receiving IFL + placebo vs 20.3 months for patients receiving IFL + bevacizumab. This increase in survival was highly statistically significant (P0.001) and is the largest increase seen in an MCRC clinical trial of this size. The early separation of the survival curves indicates the survival benefit is a treatment effect across all subgroups of p